Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103265 | 1.00 | ALDH1A1 (0.34) | ALDH1A1TP53KDM4EHSD17B10MAPT | |
| SCHEMBL3109514 | 0.90 | HRH3 (0.36) | ALDH1A1HSD17B10MAPTNPC1RAB9A | |
| SCHEMBL3109508 | 0.90 | HRH3 (0.36) | ALDH1A1HSD17B10MAPTNPC1RAB9A | |
| SCHEMBL13098918 | 0.89 | MAPT (0.35) | ALDH1A1TP53MAPTRAB9AHRH3 | |
| SCHEMBL13098869 | 0.88 | MAPT (0.37) | ALDH1A1KDM4EMAPTNPC1RAB9A | |
| SCHEMBL13098856 | 0.87 | ALDH1A1 (0.38) | ALDH1A1TP53KDM4EHSD17B10MAPT | |
| SCHEMBL13098861 | 0.85 | ALDH1A1 (0.36) | ALDH1A1TP53KDM4EHSD17B10MAPT | |
| SCHEMBL3110248 | 0.84 | HRH3 (0.34) | MAPTHRH3USP2 | |
| SCHEMBL13099133 | 0.83 | MAPT (0.35) | TP53MAPT | |
| SCHEMBL6134823 | 0.83 | HRH3 (0.38) | MAPTSMN1; SMN2HRH3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204379-A1 | POLYPEPTIDE COMPOUND | Astellas Pharma Inc. (JP) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256048-A1 | POLYPEPTIDE COMPOUND | VIP, ANPEP, NPEPPS | ALDH1A1 4854/4885TP53 3879/4885KDM4E 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.